5 Largest Canadian Cannabis LPs - 13% This Week; -26% In Last 6 Weeks
To help you with your investment decisions, this article presents
- the stock performance of each of the 5 largest Canadian cannabis licensed producers (LPs) in the munKNEE Canadian Cannabis LPs Index this week and in the last 6 weeks in descending order,
- the average 12-month stock price targets (source) for each constituent according to the analysts that cover these companies,
- the percentage change from today's price,
- the consensus buy, hold and sell recommendations, and
- the percentage chance of encountering financial distress over the next 2 years (source)
- Cronos (CRON): DOWN 11.1% this week and DOWN 22.5% in the last 6 weeks
- 18 analysts have:
- an average year-end price target of $1.99 representing
- a 33.7% increase from the March 10th price of $1.93 and
- a consensus BUY rating and, according to an analysis by macroaxis.com, has
- a 3% chance of going through some form of financial distress in the next two years.
- 18 analysts have:
- Tilray (TLRY): DOWN 14.5% this week and DOWN 24.6% in the last 6 weeks
- 22 analysts have:
- an average year-end price target of $2.64 representing
- a 9.1% increase from the March 10th price of $2.42 and
- a consensus BUY rating and, according to an analysis by macroaxis.com, has
- a 68% chance of going through some form of financial distress in the next two years.
- 22 analysts have:
- Aurora (ACB): DOWN 11.9% this week and DOWN 27.5% in the last 6 weeks
- 14 analysts have:
- an average year-end price target of $1.32 representing
- a 44.6% increase from the March 10th price of $0.74 and
- a consensus HOLD rating and, according to an analysis by macroaxis.com, has
- a 78% chance of going through some form of financial distress in the next two years.
- 14 analysts have:
- OrganiGram (OGI): DOWN 16.5% this week and DOWN 28.3% in the last 6 weeks
- 15 analysts have:
- an average year-end price target of $1.50 representing
- a 107.6% increase from the March 10th price of $0.66 and
- a consensus BUY rating and, according to an analysis by macroaxis.com, has
- a 49% chance of going through some form of financial distress in the next two years.
- 15 analysts have:
- Canopy Growth (CGC): DOWN 10.9% this week and DOWN 30.0% in the last 6 weeks
- 23 analysts have:
- an average year-end price target of $2.22 representing
- a 4.9% increase from the March 10th price of $2.05 and
- a consensus SELL rating and, according to an analysis by macroaxis.com, has
- a 53% chance of going through some form of financial distress in the next two years.
- 23 analysts have:
More By This Author:
Ayr Wellness Q4 Financials: Operating Loss Increases; EBITDA Improves
MindMed: Researching LSD And MNMA To Treat Neurological Diseases
Trulieve Q4 Financials: Revenue Static; Net Loss Reduced By 33%
Disclosure: None
Visit munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample more